All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

aspartic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1550	56-84-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: L-Aspartic acid asparagic acid aspartic acid	One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter. Molecular weight: 133.10 Formula: C4H7NO4 CLOGP: -2.41 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 100.62 ALOGS: 0.03 ROTB: 3

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	643.97 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Foetal growth restriction	91.03	83.16	15	100	7538	63481369

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
CHEBI has role	CHEBI:25512	neurotransmitters
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76971	Escherichia coli metabolites
CHEBI has role	CHEBI:78675	fundamental metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypokalemia	indication	43339004
Hypokalemia Prevention	indication
Hyperkalemia	contraindication	14140009
Complete atrioventricular block	contraindication	27885002
Gastrointestinal ulcer	contraindication	40845000
Congenital myotonia, autosomal dominant form	contraindication	57938005
Acute nephropathy	contraindication	58574008
Diarrhea	contraindication	62315008
Kidney disease	contraindication	90708001	DOID:557
Gastrointestinal obstruction	contraindication	126765001
Gastroparesis	contraindication	235675006
Chronic diarrhea	contraindication	236071009
Hyporeninemic hypoaldosteronism	contraindication	236464008
Familial hyperkalemic periodic paralysis	contraindication	304737009	DOID:14451
Severe dehydration	contraindication	450316000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.45	acidic
pKa2	3.18	acidic
pKa3	10.47	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Calcium-binding mitochondrial carrier protein Aralar1	Transporter	O75746	CMC1_HUMAN					WOMBAT-PK
Aspartate aminotransferase, cytoplasmic	Enzyme	P17174	AATC_HUMAN					WOMBAT-PK
Aspartoacylase	Enzyme	P45381	ACY2_HUMAN					WOMBAT-PK
Asparagine synthetase [glutamine-hydrolyzing]	Enzyme	P08243	ASNS_HUMAN					WOMBAT-PK
Argininosuccinate synthase	Enzyme	P00966	ASSY_HUMAN					WOMBAT-PK
Aminoacylase-1	Enzyme	Q03154	ACY1_HUMAN					WOMBAT-PK
Aspartate aminotransferase, mitochondrial	Enzyme	P00505	AATM_HUMAN					WOMBAT-PK
Aspartate--tRNA ligase, cytoplasmic	Enzyme	P14868	SYDC_HUMAN					WOMBAT-PK
Aspartyl/asparaginyl beta-hydroxylase	Enzyme	Q12797	ASPH_HUMAN					WOMBAT-PK
Excitatory amino acid transporter 1	Transporter	P43003	EAA1_HUMAN		IC50	5.03		CHEMBL
Excitatory amino acid transporter 2	Transporter	P43004	EAA2_HUMAN		IC50	4.50		CHEMBL
Excitatory amino acid transporter 3	Transporter	P43005	EAA3_HUMAN		IC50	4.71		CHEMBL
Calcium-binding mitochondrial carrier protein Aralar2	Transporter	Q9UJS0	CMC2_HUMAN					WOMBAT-PK
Glutamate NMDA receptor	Ion channel		NMDZ1_RAT NMDE1_RAT NMDE2_RAT NMDE3_RAT NMDE4_RAT NMD3B_RAT NMD3A_RAT		IC50	5.79		CHEMBL
Excitatory amino acid transporter 4	Transporter		EAA4_RAT		IC50	4.96		CHEMBL
Glutamate transporter homolog	Transporter		GLT_PYRHO		Kd	9		CHEMBL
4-hydroxy-tetrahydrodipicolinate synthase	Unclassified		DAPA_ECOLI		Ki	4.05		CHEMBL

External reference:

ID	Source
4018680	VUID
N0000146991	NUI
D00013	KEGG_DRUG
4018680	VANDF
C0004015	UMLSCUI
CHEBI:22660	CHEBI
ASP	PDB_CHEM_ID
CHEMBL274323	ChEMBL_ID
D001224	MESH_DESCRIPTOR_UI
DB00128	DRUGBANK_ID
3309	IUPHAR_LIGAND_ID
1570	INN_ID
30KYC7MIAI	UNII
5960	PUBCHEM_CID
1169	RXNORM
NOCODE	MMSL
000933	NDDF
44970006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.32 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.32 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.32 g	INTRAVENOUS	NDA	23 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3200	SOLUTION	434 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3205	SOLUTION	434 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	434 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	434 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	434 mg	INTRAVENOUS	ANDA	20 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9341	SOLUTION	0.32 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9361	SOLUTION	0.19 g	INTRAVENOUS	NDA	23 sections
ProSol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0499	INJECTION, SOLUTION	600 mg	INTRAVENOUS	NDA	21 sections
ProSol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0499	INJECTION, SOLUTION	600 mg	INTRAVENOUS	NDA	21 sections
Clinisol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0502	INJECTION, SOLUTION	434 mg	INTRAVENOUS	ANDA	18 sections
Clinisol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0502	INJECTION, SOLUTION	434 mg	INTRAVENOUS	ANDA	18 sections
Clinisol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0502	INJECTION, SOLUTION	434 mg	INTRAVENOUS	ANDA	18 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1130	INJECTION, SOLUTION	0.32 g	INTRAVENOUS	ANDA	15 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1130	INJECTION, SOLUTION	0.32 g	INTRAVENOUS	ANDA	15 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1130	INJECTION, SOLUTION	0.32 g	INTRAVENOUS	ANDA	15 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1131	INJECTION, SOLUTION	0.19 g	INTRAVENOUS	ANDA	15 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1131	INJECTION, SOLUTION	0.19 g	INTRAVENOUS	ANDA	15 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1131	INJECTION, SOLUTION	0.19 g	INTRAVENOUS	ANDA	15 sections
Aminosyn-PF	HUMAN PRESCRIPTION DRUG LABEL	18	0409-4178	INJECTION, SOLUTION	370 mg	INTRAVENOUS	NDA	14 sections
Aminosyn II	HUMAN PRESCRIPTION DRUG LABEL	17	0409-7171	INJECTION, SOLUTION	1050 mg	INTRAVENOUS	NDA	19 sections
Aminosyn II	HUMAN PRESCRIPTION DRUG LABEL	17	0409-7172	INJECTION, SOLUTION	700 mg	INTRAVENOUS	NDA	19 sections
Aminosyn-PF	HUMAN PRESCRIPTION DRUG LABEL	18	0990-4178	INJECTION, SOLUTION	370 mg	INTRAVENOUS	NDA	13 sections
Aminosyn-PF	HUMAN PRESCRIPTION DRUG LABEL	18	0990-4178	INJECTION, SOLUTION	370 mg	INTRAVENOUS	NDA	13 sections
Aminosyn-PF	HUMAN PRESCRIPTION DRUG LABEL	18	0990-4179	INJECTION, SOLUTION	527 mg	INTRAVENOUS	NDA	14 sections
Aminosyn-PF	HUMAN PRESCRIPTION DRUG LABEL	18	0990-4179	INJECTION, SOLUTION	527 mg	INTRAVENOUS	NDA	14 sections
Aminosyn II	HUMAN PRESCRIPTION DRUG LABEL	17	0990-7171	INJECTION, SOLUTION	1050 mg	INTRAVENOUS	NDA	19 sections
Aminosyn II	HUMAN PRESCRIPTION DRUG LABEL	17	0990-7171	INJECTION, SOLUTION	1050 mg	INTRAVENOUS	NDA	19 sections